No Data
In 2024, Jiangsu Hengrui Pharmaceuticals achieved record high revenue and net profit, with explosive growth in Innovative Drugs and research and development investment accounting for nearly 30% of revenue | Earnings Reports insights.
Net income is 6.337 billion yuan, a sharp increase of 47.28% year-on-year. Innovative Drugs sales reached 13.892 billion yuan, a year-on-year growth of 30.60%, accounting for nearly 50% of total revenue, becoming the core engine for performance growth.
Another 13 companies added this week! Midea Group Co., Ltd and several other stocks have disclosed plans for shareholding and repurchase loan plans. A list of related A-shares is provided.
① According to incomplete Statistics, as of the time of publication, 13 listed companies disclosed information related to repurchase Shareholding and refinancing this week (attached table); ② Midea Group Co., Ltd received the highest special loan amount, with the loan amount not exceeding 9 billion yuan.
China Tourism Group Duty Free Corporation's revenue and net profit both decreased in 2024. Industry insiders expect that "this year's offshore duty-free sales will drop by another 20%" | Interpretations
China Tourism Group Duty Free Corporation announced that in 2024, it will achieve revenue of 56.474 billion yuan, a year-on-year decrease of 16.38%; the net income attributable to shareholders of the listed company will be 4.267 billion yuan, a year-on-year decrease of 36.44%; analysts expect that this year's sales of duty-free goods in Hainan will further decrease by about 25% compared to 2024.
Domestic Innovative Drugs are once again surging towards overseas markets! Concept stocks have responded with a significant increase. Is the external authorization model the optimal choice?
① As of the time of publication, the Hang Seng Innovative Drugs Index has risen over 5%, with multiple Innovative Drugs concept stocks experiencing double-digit gains; ② In recent days, Jiangsu Hengrui Pharmaceuticals, Hepo Pharmaceutical, UNITED LAB, and other Biotech companies have issued announcements about "going abroad"; ③ Northeast Securities stated that top MNCs recognize the R&D capabilities of Chinese local companies and are more willing to assign high valuations.
Merck And Jiangsu Hengrui Pharmaceuticals Entered Into An Exclusive License Agreement For HRS-5346, An Investigational Oral Small Molecule Lipoprotein(a) Inhibitor Currently In A Phase 2 Trial In China, Hengrui Pharma Will Receive An Upfront Payment...
Real reversal or short-term warming? A surge in distributed photovoltaic installations is happening, with some Dealers claiming to have encountered "order cancellations".| Fax
① Under the rush of photovoltaic installations, an outbreak of demand has led to insufficient supply, causing conflicts in production and sales, with some Dealers claiming that they have had their orders "canceled" by component manufacturers; ② Dealers state that their current focus is entirely on the rush of installations for the two key deadlines of April 30 and May 31, feeling overworked and primarily concentrating on installation; ③ Analysis suggests that the current emphasis on controlling production capacity in the photovoltaic Industry has reached an unprecedented level, which will effectively alleviate the situation of oversupply.